Drug-eluting stents - reviewing the review

Michael Želízko

Interv Akut Kardiol. 2007;6(2):39-40  

In-stent thrombosis risk factors

Roman Kollros, Pavel Boček, Ivan Šubrt, František Šefrna

Interv Akut Kardiol. 2007;6(2):47-49  

Background: Acute or subacute in-stent thrombosis (IST) is a rare, but frightened complication in patients treated with percutaneous coronary intervention (PCI). There are many factors influencing appearance of IST. Some are well known, but influence of the presence of polymorphism in prothrombotic genes is not clearly established – data from the studies concerning of this problem are unconsistent and controversial. Aim: To assess importance of the presence of genetical abnormality (polymorphism in prothrombotic genes, i. m. Leiden mutation in gene for coagulation factor V, polymorphism in gene for prothrombin and in gene for MTHFR –...

Does drug eluting stent increase long-term mortality?Results of prospective Liberec registry

František Holm, David Horák, Radomír Šimek, Zdeněk Šembera, Vladimír Hraboš

Interv Akut Kardiol. 2007;6(2):50-55  

Use of drug eluting stents (DES) decrease incidence of in-stent restenosis (ISR). However, mortality and non-fatal myocardial infarction (MI) is not influenced. Last year, there appeared first information on possibly higher incidence of death/MI due to late stent thrombosis. Aim of study and method: Analysis of long-term results of prospective non-randomized registry of patients treated by implantation of sirolimus eluting stent (SES). Primary end-point was total mortality, target lesion revascularization (TLR) and clinical in-stent restenosis. The patients were followed-up only clinically and coronary angiography was not performed routinely, only...

Heart failure with preserved ejection fraction

Vojtěch Melenovský, Jiří Kettner

Interv Akut Kardiol. 2007;6(2):56-60  

It has been increasingly recognized that half of patients hospitalized for heart failure has relatively preserved systolic function of the left ventricle. Prevalence of this type of heart failure is increasing and long-term prognosis is similarly dismal as in systolic dysfunction. In its typical form, this disease occurs in older patients, more in females, with long history of arterial hypertension and/or diabetes, who have concentric left ventricular hypertrophy or remodeling, dilated left atrium and abnormalities of diastolic ventricular filling. Despite so frequent, pathophysiology of this disease is not completely elucidated. Besides abnormal diastolic...

Solubilný ligand CD40 a akútne koronárne syndrómy

Róbert Ševčík, Jan Vojáček, Josef Bis, Jaroslav Dušek, Josef Šťásek, Radek Pudil

Interv Akut Kardiol. 2007;6(2):61-64  

Súčasný výskum sa sústredí na molekuly, ktorými by sme mohli detekovať skoršie štádiá akútnych koronárnych syndrómov ako sme schopní s troponínmi. Solubilný CD40L predstavuje unikátne spojenie medzi trombózou a lokálnym zápalovým procesom. Podľa klinických údajov sú jeho zvýšené hladiny spojené s vysokým rizikom smrtelného infarktu myokardu, chronického srdcového zlyhania alebo rekurentného infarktu u pacientov s akútnym koronárnym syndrómom. Mohol by odhaliť pacientov, ktorí by profitovali z terapie IIb/IIIa antagonistami a stratifikovať riziko trombózy pred plánovanou implantáciou stentu. K definitívnemu stanovisku sú potrebné ďalšie štúdie.

CURRENT INDICATIONS FOR THE IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY IN CORONARY ARTERY DISEASE AND CHRONIC HEART FAILURE: GUIDELINES AND CLINICAL PRACTICE

Jan Bytešník

Interv Akut Kardiol. 2007;6(2):65-69  

An implantable cardioverter-defibrillator is accepted as the most reliable treatment to improve the prognosis of patients with higher risk of sudden cardiac death. It is fully accepted as a secondary preventive indication in patients with documented sustained ventricular tachyarrhythmia in structural heart disease. The results of several randomised prospective studies also had an impact on the extension of the so-called primary preventive indications for this type of therapy. In patients with severe chronic heart failure and ventricular dyssynchrony, the combination of implantable cardioverter-defibrillator and cardiac resynchronisation therapy proves...

THROMBEMBOLECTOMY OF THE GIANT THROMBUS FROM THE RIGHT ATRIUM AND BRANCHES OF PULMONARY ARTERY

Róbert Ševčík, Jan Dominik, Josef Bis, Vratislav Dědek, Miroslav Měšťan, Jakub Radocha, Martin Tuna

Interv Akut Kardiol. 2007;6(2):70-72  

The case report describes diagnosis and therapy of a patient with deep venous thrombosis and giant thrombembolus localised in the right atrium and pulmonary artery. Etiology of deep venous thrombosis is most probably in a congenital thrombogenic state- mutation in the factor II gene: FII20210A in the heterozygot form was confirmed. This mutation results in elevated levels of prothrombin due to increased prothrombin synthesis, and is associated with a 3-fold increase in the risk for venous thrombosis. Giant thrombembolus has been seen as a complication in patients with central venous catheter, thrombi from deep venous thrombosis are usually not so...